Publications by authors named "N Horiguchi"

Layered zinc(II) hydroxides (LZH) intercalating the deprotonated forms of -(-) or -(+)-1,1'-binaphthyl-2,2'-diyl hydrogenphosphate (denoted as - or -BNDHPH, respectively) were prepared from Zn(NO) at pH 5 and 60 °C by the mixing method. The obtained hybrid compounds (denoted as - or -BNDHP/LZH, respectively) were heated from room temperature up to 800 °C under nitrogen atmosphere. According to the thermal gravimetric/differential thermal analysis measurements, hydroxyl groups were dehydrated at 270-400 °C, followed by the decomposition of organic components at 420-600 °C.

View Article and Find Full Text PDF

Psychosis is a distressing symptom commonly occurring in people with dementia. To treat Parkinson's disease psychosis, pimavanserin (), a 5-HT receptor inverse agonist having minimal 5-HT receptor affinity and no dopamine D receptor affinity, was approved in the United States, but not for dementia-related psychosis due to limited efficacy issues. Herein, we report on the identification of a potent and dual 5-HT and 5-HT receptor inverse agonist having minimal hERG inhibition, after having demonstrated the involvement of both 5-HT and 5-HT receptors to deliver antipsychotic efficacy in an MK-801-induced locomotor model and having conducted 5-HT and 5-HT occupancy studies including a surrogate method.

View Article and Find Full Text PDF

Background And Aims: Early gastric cancers (EGCs) after Helicobacter pylori (H. pylori) eradication often appear as reddish depressed lesions (RDLs); the same features are also appeared in benign stomachs after eradication. We compared clinic-pathological and endoscopic features of benign and neoplastic RDLs after H.

View Article and Find Full Text PDF
Article Synopsis
  • BACE1 is a key target for Alzheimer's treatment, but existing drugs also affect BACE2, a related protease with unclear functions.
  • Researchers found that BACE2 is responsible for shedding VEGFR3, a receptor linked to lymphatic growth; blocking BACE2 increases the receptor levels and its signaling in lymphatic cells.
  • This study highlights sVEGFR3 as a valuable blood marker for BACE2 activity, paving the way for safer Alzheimer's drugs that selectively inhibit BACE1.
View Article and Find Full Text PDF